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Available online 7 May 2016A mesonephric adenocarcinoma of the cervix is a very rare tumor deriving from remnants of the mesonephric
duct. Differential diagnosis from other cervical carcinomas is difﬁcult and little is known regarding its biological
behavior, prognosis, and the optimalmanagement strategy.Wepresent a case of amesonephric adenocarcinoma
of the cervix with a comprehensive review of the existing literature. In this case a 66-year-old woman presented
with postmenopausal vaginal bleeding. Shewas diagnosedwith a FIGO stage IIBmesonephric adenocarcinoma of
the cervix and treated with neoadjuvant chemoradiotherapy and a Wertheim hysterectomy. The recovery from
surgery was uneventful and the patient remains with no evidence of disease with 2 years of follow-up.
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1.1. Clinical presentation
A 66-year-old woman with no medical history presented with post-
menopausal vaginal bleeding. In speculo a small punctiform oriﬁce on the
right side of the cervical ostiumwas observed. Transvaginal ultrasound re-
vealed a mass of 2 by 2 cm in de right lateral cervical wall, palpable as a
hard nodulewithout extension to the pelvicwall. Taking into consideration
there was a mass in a suspicious-looking cervix an immediate conization
was performed. The patient had a normal PAP smear 2 years before. The
pathological examination of the conus revealed the presence of an inva-
sive mesonephric adenocarcinoma of the cervix, characterized by inﬁl-
trating tubular structures containing eosinophilic, hyaline secretions in
their lumens (Fig. 1A). The tubular structures were lined by cuboidal ep-
ithelium exhibitingmild to moderate nuclear atypia. Immunohistochem-
ical stainings for PAX8, p16 and CD10 were positive (Fig. 1C).
There was extension of tumor cells in all resectionmargins. Magnet-
ic Resonance Imaging (MRI) performed after the conization showed a
mass in the right side of the cervix, measuring 38 × 35 × 38 mm, with
extension to the uterus, the right parametrium and the upper part of
the vagina (Fig. 2). These clinical ﬁndings corresponded with an Inter-
national Federation of Gynecology and Obstetrics (FIGO) stage IIB.
A Positron Emission Tomography (PET) scan showed no evidence of
pathological lymphadenopathies or distant metastases. The CA-125
blood serum level was normal.rest. No ﬁnancial support.
kx).
. This is an open access article under1.2. Treatment
Given the presence of a bulky tumor with parametrial invasion,
the patient underwent neoadjuvant chemoradiotherapy: 50 Gy
(Gray) of Intensity Modulated Radiation Therapy (IMRT) in 25 frac-
tions of 2 Gy daily and concomitant chemotherapy (Cisplatin) once
a week. There was a limited reduction in size of the cervical mass
to a volume of 37 × 23 × 30 mm. After the neoadjuvant therapy the
patient underwent a type 2 Wertheim hysterectomy without pelvic
lymphadenectomy.
Histopathologic examination conﬁrmed the presence of a meso-
nephric adenocarcinoma, predominantly on the right side, however,
with almost complete circumferential extension. The lesion mea-
sured 3 cm in greatest dimension. There was extension to the isth-
mus and the paracervical fat tissue. The resection margins were
free of tumor.
The lesion stained for cytokeratin 7, EMA and vimentin. Stainings for
calretinin, carcinoembryonic antigen (CEA), estrogen and progesterone
receptor (ER/PR) were negative.
The ﬁnal diagnosis was a mesonephric adenocarcinoma of the cer-
vix, FIGO stage IIB. Tumor cells expressed p16, but chromogenic in situ
hybridization did not demonstrate low- or high-risk Human Papilloma-
virus (HPV).1.3. Outcome and follow up
The patient did not receive adjuvant therapy and she remains with
no evidence of disease with 2 years of follow-up, with control visits
every 3 months and MRI- and PET-scans every 12 months.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A, The lesion shows inﬁltrating tubular structures containing eosinophilic, hyaline secretions (original magniﬁcation, ×200). B, The tubular structures are lined by cuboidal tumor
cells demonstrating mild to moderate nuclear atypia (original magniﬁcation, ×400). C, The tumor cells show strong nuclear expression of the transcription factor PAX8
(immunohistochemistry for PAX8, original magniﬁcation ×200). D, There is nuclear and cytoplasmic expression of the tumor suppressor p16 (immunohistochemistry for p16, original
magniﬁcation ×200).
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2.1. Deﬁnition
In order to understand the origin of this tumor we recapitulate the
embryology in the supplementary material.2.2. Incidence
To the best of our knowledge there are only 40 cases of this tumor
reported in the literature to date, including present case (Table 2). The
incidence of this neoplasm is uncertain since it is often confused with
more common adenocarcinomas or mistaken for benign ﬂorid meso-
nephric hyperplasia (Hart, 2002; Ferry and Scully, 1990; Kenny et al.,
2012).2.3. Diagnosis
The mean age at the time of diagnosis was 52 years in this literature
review. Unlike the more common squamous epithelial carcinoma, this
type of cervical cancer is rarely discovered by PAP smear
(Anagnostopoulos et al., 2012). Most patients present with abnormal
vaginal bleeding, oftenwith a visible cervical lesion (Hart, 2002). The di-
agnosis is usually made on biopsy specimens, endometrial curettings or
hysterectomy specimens. A common ﬁnding on endometrial biopsy is a
coexisting endometroid adenocarcinoma (Anagnostopoulos et al.,
2012).
Most tumors exhibit a widely inﬁltrative and conﬂuent pattern of
growth and extension into the lower uterine segment is common
(Nomoto et al., 2013). Because of the widespread distribution within
the cervix at the time of diagnosis the initial site of origin in the lateral
part of the cervix is often no longer apparent (Kenny et al., 2012), as
was in this case.2.4. Pathology
One of the most characteristic features of a mesonephric adeno-
carcinoma is that it exhibits a mixture of morphologic patterns.
Therefore they are often confused with serous, clear cell or
endometroid adenocarcinomas (Anagnostopoulos et al., 2012;
Nomoto et al., 2013).
In this literature review 23% of the reported mesonephric carcino-
mas were associated with a spindled cell component (malignant
mixed mesonephric tumor, MMMT). This is a biphasic variant of a me-
sonephric carcinoma with sarcomatoid features (Clement et al., 1995;
Yap et al., 2006).
The typical background lesion of a mesonephric carcinoma is ﬂor-
id mesonephric hyperplasia, characterized by a densely eosinophilic
luminal secretion (Menon et al., 2013). In contrast to mesonephric
hyperplasia, a mesonephric carcinoma does not have a lobular archi-
tecture and the nuclei appear cytological malignant. The Ki-67 prolif-
eration index is less than 1% in mesonephric hyperplasia compared
to 15–20% in mesonephric carcinoma (Silver et al., 2001).2.5. Immunohistochemistry
Given its potential mimicry of other neoplasms, immunohistochem-
istry can be helpful in the differential diagnosis (Table 1). Positive im-
munostaining for CD10, CK7 and calretinin along with a negative
immunostaining for CEA is suggestive for a mesonephric origin (Silver
et al., 2001). Mesonephric adenocarcinoma is also usually positive for
epithelial membrane antigen (EMA) (Silver et al., 2001) and vimentin
(Clement et al., 1995; Silver et al., 2001; Lang and Dallenbach-
Hellweg, 1990) whereas ER/PR are usually absent (Silver et al., 2001).
Mesonephric adenocarcinoma is oneof the few subtypes of cervical can-
cer that is not related to HPV (Kenny et al., 2012).
PAX8 staining is usually positive inmesonephric carcinomas (Kenny
et al., 2012; Fregnani et al., 2008). CA125 is also usually positive in
Fig. 2.Axial and sagittal T2MRI image of the patient before treatment. Arrows indicate the cervical tumor on the right side of the cervix, measuring 38 × 35× 38mm,with extension to the
uterus, the right parametrium and the upper part of the vagina.
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2.6. Treatment
In the 39 cases described in the literature, treatment depended on
the stage of the disease and consisted of hysterectomy (HRT) with or
without bilateral salpingo-oophorectomy (BSO), pelvic lymphadenec-
tomy (LA) and (neo-) adjuvant chemo- or radiotherapy.
In the present literature review the vast majority of patients (70%)
were diagnosed at a stage I. All patients with stage I carcinoma, except
for two, were treatedwith HRT and BSO, and LAwas performed in eigh-
teen patients (64%). No adjuvant treatment was given in patients with
stage I disease except for radiotherapy in ﬁve patients with adenocarci-
noma (AC) and chemotherapy in one patient with a mesonephric ade-
nocarcinoma with spindled cell component (MMMT). There seems to
be no difference in disease recurrence andmean recurrence interval be-
tween the patients with stage I mesonephric AC of the cervix treated
merely surgically and those who received adjuvant therapy afterwards
(Table 2). However, the biological behavior of this unusual tumor re-
mains unclear and until there are sufﬁcient data to recommend a partic-
ular course of therapy it seems reasonable to manage patients with
mesonephric adenocarcinoma of the cervix according to current guide-
lines for cervical adenocarcinoma of similar stage.
2.7. Prognosis
Owing to the small number of cases with adequate follow-up, prog-
nosis cannot be accurately predicted but it seems that mesonephric car-
cinomas carry aworse prognosis. Patientswith a stage Imesonephric ACTable 1
Immunohistochemical staining proﬁle ofmesonephric, endocervical and endometroid ad-
enocarcinoma of the cervix and the present case.
Present
case
Mesonephric
adenocarcinoma
Endocervical
adenocarcinoma
Endometroid
adenocarcinoma
PAX8 + + + +
Calretinin − + − −
CD10 + + − −
CK7 + + + +
Vimentin + + − +
EMA + + + +
CEA − − + −
ER/PR − − − +
HPV − − + −had a recurrence rate of 32% and a mean recurrence interval of
24 months (Table 2), compared to a reported recurrence rate of 11%
for squamous cell carcinomas and 16% for adenocarcinomas in early
stage cervical cancer (Fregnani et al., 2008). However, these results
should be interpreted with caution given the small number of patients.
Four out of 24 patients diagnosed at stage I with adequate follow up
available died of the disease, with a mean survival of 50 months. All of
the patients diagnosed at stage IV had a spindled cell component.
Only ﬁve of the nine reported cases of MMMT were diagnosed at
stage I, two were stage II and two were stage IV. It seems that meso-
nephric carcinomas with a spindled cell component are diagnosed at a
more advanced stage, implying a worse prognosis.3. Conclusion
A mesonephric adenocarcinoma of the cervix arises from remnants
of the mesonephric (Wolfﬁan) duct in the lateral wall of the cervix. It
is a rare type of cervical cancer, to the best of our knowledge only 40
cases have been reported in literature.
The most common symptom is postmenopausal bleeding. Because
of its localization, this type of cervical cancer is rarely discovered on
PAP smear. Diagnosis is made for themost part on biopsy or hysterecto-
my specimens. Because of its widely inﬁltrative growth potential a bar-
rel-shaped cervix can occur. If a barrel-shaped cervix is palpated during
pelvic examination, an adenocarcinoma of the cervix should be
considered.
It is a pathologically challenging diagnosis since a mesonephric ade-
nocarcinoma typically exhibits a mixture of morphologic patterns.
Therefore they are often confused with more common adenocarci-
nomas. The incidence of mesonephric carcinoma is probably
underestimated because of this frequent misclassiﬁcation. The possibil-
ity of amesonephric carcinoma of the cervix should be consideredwhen
encountering a histological unusual-appearing carcinoma or MMMT. In
this case a targeted search for associatedmesonephric hyperplasia is re-
quired, characterized by small glands or tubuleswith eosinophilic lumi-
nal secretions. In questionable cases, immunohistochemical proﬁling
can be helpful.
Prognosis cannot be accurately predicted owing to the small
number of cases with sufﬁcient follow up but it seems that meso-
nephric carcinomas carry a worse prognosis. In this review the ma-
jority of patients (70%) were diagnosed at stage IB with a mean age
of 52 years.
Treatment consisted of hysterectomy, bilateral salpingo-oophorec-
tomy and pelvic lymphadenectomy in the majority of these patients.
Table 2
summary of the 40 cases of mesonephric carcinoma of the cervix reported in the literature, including present case.
Author Year Case Age Symptoms Tumor type Stage Treatment Clinical course Outcome
McGee 1962 1 36 PC VBV AC IB HRT Pelvic R (6 yr): NFT DOD 7 yr
Buntine 1979 2 48 ‘ﬁbroids’ AC / HRT + BSO Vaginal R (7 yr): NFT DOD 9 yr
Valente & Susin 1987 3 58 PMP VBV AC IB1 HRT + BSO + LA Pelvis, sacral R (2 yr): RT DOD 2.8 yr
Lang 1990 4 46 Cervical polyp AC / HRT RT NED 10mo
5 55 / AC IB HRT / /
Ferry & Scully 1990 6 55 Pelvic relaxation AC / HRT + BSO RT NED 5 yr
Stewart 1993 7 37 Constipation, menorrhagia AC I HRT + BSO + LA NFT NED 10 yr
Clement 1995 8 46 Menorrhagia, “ﬁbroid uterus” AC IB HRT + BSO + LA NFT NED 2 yr
9 34 Menometrorrhagia AC IB HRT + BSO + LA Abd R (1 yr): CT NED 2 yr
10 71 AC on PAP smear, pelvic mass AC IB HRT + BSO + LA RT, abd R (4 mo): CT DOD 8,5mo
11 67 PMP VB AC IB HRT + BSO + LA / /
12 37 PC VB MMMT IB HRT + BSO + LA Adj CT, abd R (9 & 11 yr): CT AWD 13 yr
13 73 PMP VB MMMT IB HRT + BSO RT NED 3 yr
14 40 Menorrhagia, cervical polyp MMMT IB HRT + BSO RT NED 2.3 yr
Silver 2001 15 62 PMP VB AC IB HRT + USO NFT NED 1.5 yr
16 47 Uterine prolapse AC IB HRT + BSO NFT NED 2.1 yr
17 40 SIL on PAP smear AC IB HRT + BSO NFT NED 3.2 yr
18 54 PMP VB AC IB HRT + BSO + LA NFT NED 6.1 yr
19 67 PMP VB AC IB HRT + BSO NFT NED 8.3 yr
20 72 AGC on PAP smear AC IB HRT + BSO + LA RT, rectovaginal R (1.7 yr): CT NED 2.5 yr
21 39 Menorrhagia, cervical “ﬁbroid” MMMT IB HRT + BSO Mediastinal metastasis (5.6 yr): CT DOD 6.2 yr
22 62 PMP VB AC IB HRT + BSO + LA NFT /
23 56 Right ovarian cystadenoma AC / HRT + BSO NFT NED 7.4 yr
24 35 VB, pelvic pain AC IIB RT Pelvic R (2.2 yr):CT DOD 3.2 yr
25 43 Metrorrhagia, anemia MMMT IVB HRT + BSO + LA + O CT, bladder & pelvic R (8 mo): RT DOD 10 mo
Angeles 2004 26 47 Menometrorrhagia, pelvic pain AC IIA HRT + BSO RT NED 1 yr
Bagué 2004 27 41 Abnormal VB AC IB HRT + BSO + LA + A RT NED 11.4 yr
28 24 / AC IIA / / /
29 45 PC VB AC IB1 HRT + USO NFT NED 3.1 yr
30 54 PMP VB MMMT IIA HRT + BSO + LA + O NFT DOD 7 mo
31 62 / MMMT IVB HRT + BSO CT & RT, bone R AWD 3.3 yr
32 54 / MMMT IB1 HRT + BSO + LA + O NFT NED 1.1 yr
Yap 2006 33 54 PMP VB AC IB1 HRT + BSO + LA RT NED 3.1 yr
Fukunaga 2008 34 46 Abnormal VB AC IB HRT + BSO + LA + O NFT NED 4 mo
Anagnostopoulos 2012 35 64 Suspicious looking cervix AC IB1 HRT + BSO + LA NFT NED 6 mo
Nomoto 2012 36 64 PMP VB AC IB1 HRT + BSO + LA Multifocal lung metastases (1 yr): CT /
37 64 PMP VB AC IB1 HRT + BSO + LA NFT /
Meguro 2013 38 63 PMP VB MMMT IIA HRT + BSO + LA Local R (7 mo): CRT NED 7 mo
Menon 2013 39 65 PMP VB AC IB1 HRT + BSO + LA RT NED 6 mo
Present case 2013 40 66 PMP VB AC IIB CRT + HRT + BSO NFT NED 2 yr
PMP VB: postmenopausal vaginal bleeding. PC VB: postcoital vaginal bleeding. HRT: hysterectomy. BSO: bilateral salpingo-oophorectomy. USO: unilateral salpingo-oophorectomy LA:
lymphadenectomy. O: omentectomy. A: appendectomy. AC: adenocarcinoma. MMMT: malignant mixed mesonephric tumor. CT: chemotherapy. RT: radiotherapy. CRT: chemo- and ra-
diotherapy. NFT: no further treatment. R: recurrence. Yr: year. Mo: month. NED: no evidence of disease. AWD: alive with disease. DOD: dead of disease.
10 A. Dierickx et al. / Gynecologic Oncology Reports 17 (2016) 7–11The recurrence rate in these patients was 32% and themean recurrence
interval 24 months.
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